^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ZMYM2 (Zinc Finger MYM-Type Containing 2)

    i
    Other names: ZMYM2, Zinc Finger MYM-Type Containing 2, RAMP, FIM, Zinc Finger Protein 198, ZNF198, MYM, Fused In Myeloproliferative Disorders Protein, Zinc Finger MYM-Type Protein 2, Rearranged In Atypical Myeloproliferative Disorder Protein, Rearranged In An Atypical Myeloproliferative Disorder, Zinc Finger, MYM-Type 2, NECRC, SCLL
    3ms
    Targeting the ZMYM2-ANXA9 Axis: Organoid Models Illuminate a Novel Pathway to Overcome Oxaliplatin Resistance in Colorectal Cancer. (PubMed, Biomedicines)
    Colorectal cancer (CRC) represents a major public health challenge [...].
    Journal
    |
    ZMYM2 (Zinc Finger MYM-Type Containing 2)
    |
    oxaliplatin
    6ms
    Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia. (PubMed, Precis Oncogenom)
    After initially responding to ponatinib, the patient was switched to pemigatinib which eventually transitioned them to a successful transplant. Leukemia cells isolated from the patient exhibited ex vivo sensitivity to ponatinib, bortezomib and axitinib. ZMYM2:FGFR1-transformed Ba/F3 cells were exquisitely sensitive to next generation FGFR inhibitors, and combinations of FGFRi plus trametinib or midostaurin were found to be synergistic, suggesting novel therapeutic options for FGFR1-fusion positive patients.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • ZMYM2 (Zinc Finger MYM-Type Containing 2)
    |
    Mekinist (trametinib) • Iclusig (ponatinib) • bortezomib • midostaurin • Pemazyre (pemigatinib) • axitinib
    7ms
    ZMYM2-FLT3 Fusion Gene: Implications for Chromosomal Instability and Proliferation in Myeloid/Lymphoid Neoplasms. (PubMed, FASEB J)
    Additionally, these inhibitors promoted apoptosis in ZMYM2::FLT3-overexpressing cells by reducing the phosphorylation levels of STAT3 and ERK. The ZMYM2::FLT3 fusion gene significantly promotes cell proliferation and genetic instability, and its effects can be mitigated using tyrosine kinase inhibitors.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • STAT3 (Signal Transducer And Activator Of Transcription 3) • ZMYM2 (Zinc Finger MYM-Type Containing 2)
    9ms
    Targeting the ZMYM2-ANXA9 Axis with FLT3 Inhibitor G749 Overcomes Oxaliplatin Resistance in Colorectal Cancer. (PubMed, Biomedicines)
    The ZMYM2-ANXA9 signaling axis drives chemoresistance and tumor progression in CRC. FLT3 inhibition by G749 effectively downregulates ANXA9 and sensitizes tumors to chemotherapy, highlighting a novel therapeutic approach for chemoresistant CRC.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • ZMYM2 (Zinc Finger MYM-Type Containing 2)
    |
    oxaliplatin • denfivontinib (SKI-G-801)
    1year
    CircZMYM2 plays a pivotal role in osteosarcoma by regulating the translation of NACA and ARPC1B. (PubMed, Heliyon)
    Mechanistically, circZMYM2 competitively bound to FXR1 to regulate the translation of NACA and ARPC1B. CircZMYM2 may be a crucial regulator of OS tumorigenesis and a potential diagnostic and therapeutic biomarker for OS patients.
    Journal
    |
    ZMYM2 (Zinc Finger MYM-Type Containing 2) • ARPC1B (Actin Related Protein 2/3 Complex Subunit 1B)
    over1year
    Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma. (PubMed, Br J Dermatol)
    Our analysis of the largest number of cLMS cases to-date highlights the importance of large cohort sizes and the exploration beyond small targeted gene panels when performing molecular analyses, as it allowed a comprehensive exploration of the mutational landscape of these tumours and identification of novel candidate driver events. It also uniquely afforded the opportunity to compare the molecular phenotype of cLMS with LMS of other tissue types, such as uterine and soft tissue LMS. Given that molecular profiling has resulted in the development of novel targeted treatment approaches for uterine and soft tissue LMS, our study now allows the same opportunities to become available for patients with cLMS.
    Clinical • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • IGF1 (Insulin-like growth factor 1) • ZMYM2 (Zinc Finger MYM-Type Containing 2) • NCOR1 (Nuclear Receptor Corepressor 1) • KDM6B (Lysine Demethylase 6B) • CRTC1 (CREB Regulated Transcription Coactivator 1) • MAML2 (Mastermind Like Transcriptional Coactivator 2) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
    |
    TP53 mutation • RB1 mutation
    over1year
    Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement t(8;13)(p11;q12): A case report and literature review. (PubMed, Oncol Lett)
    However, 6 months later, the disease progressed from EMS to AML and the patient died due to ineffective induction therapy. The present study also reviews the relevant literature about this unusual entity to enhance the understanding of EMS.
    Review • Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1) • ZMYM2 (Zinc Finger MYM-Type Containing 2)
    almost2years
    A comprehensive genomic profiling of myeloid malignancies demonstrates mutational spectrum of DNA variants, FLT3-ITDs, and gene fusions (AACR 2024)
    The Oncomine Myeloid Assay is a fast, robust, and reproducible solution for comprehensive genomic profiling of myeloid malignancies. We describe the mutational spectrum of DNA variants and RNA fusions in a range of clinical research samples. (For research use only.
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR1 (Fibroblast growth factor receptor 1) • DNMT3A (DNA methyltransferase 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CREBBP (CREB binding protein) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • ZMYM2 (Zinc Finger MYM-Type Containing 2) • CALR (Calreticulin) • KAT6A (Lysine Acetyltransferase 6A) • ANKRD26 (Ankyrin Repeat Domain Containing 26)
    |
    FLT3-ITD mutation • ASXL1 mutation • TET2 mutation • SRSF2 mutation • FGFR1 fusion
    |
    Oncomine Myeloid Assay GX • Oncomine Myeloid Research Assay